New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 28, 2012
07:34 EDTHZNPHorizon Pharma receives two additional U.S. patent allowances for DUEXIS
Horizon Pharma announced that it has received Notices of Allowance from the United States Patent and Trademark Office for U.S. Patent Application Serial No. 13/403,930 and U.S. Application Serial No. 13/403,923 both entitled "Stable Compositions of Famotidine and Ibuprofen" with claims that cover DUEXIS tablets. The Notices of Allowance conclude the substantive examination of these patent applications and will result in the issuance of U.S. patents after administrative processes are completed. The patents scheduled to issue from these applications will expire in 2028 for the U.S. patents. After issuance, Horizon plans to list the U.S. patents in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. DUEXIS is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers.
News For HZNP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2015
07:04 EDTHZNPHorizon Pharma issued additional notice of patent claims
Subscribe for More Information
August 27, 2015
07:22 EDTHZNPHorizon Pharma granted Notice of Allowance for Pennsaid by USPTO
Subscribe for More Information
August 21, 2015
13:04 EDTHZNPDepomed to file revocation statement with SEC
Subscribe for More Information
August 20, 2015
07:03 EDTHZNPHorizon Pharma issued Notice of Allowance by USPTO covering Vimovo
Subscribe for More Information
August 19, 2015
17:40 EDTHZNPDepomed sends letter to Horizon Pharma CEO
Subscribe for More Information
17:36 EDTHZNPDepomed board unanimously rejects revised proposal from Horizon Pharma
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use